Attached files

file filename
8-K - FORM 8-K - Hicks Acquisition CO II, Inc.d371090d8k.htm
0
Innovative Coating & Microencapsulation Product Solutions
Business Combination with Hicks Acquisition Company II, Inc.
June 2012
Exhibit 99.1


1
Disclaimer
1
Securities Law Information
In connection with the proposed transactions with Appleton Papers Inc. (together with its successor after converting into a limited liability company, “Appvion”) and its current owner, Paperweight Development
Corp. (“PDC”),  Hicks Acquisition Company II, Inc. (“HACII”) intends to file with the SEC a proxy statement and mail a definitive proxy statement and other relevant documents to HACII stockholders.  HACII
stockholders and other interested persons are advised to read, when available, HACII’s preliminary proxy statement, and any amendments thereto, and the definitive proxy statement in connection with
HACII’s solicitation of proxies for the special meeting to be held to approve the transactions because these proxy statements will contain important information about Appvion, HACII, and the proposed
transactions.  The definitive proxy statement will be mailed to HACII stockholders as of a record date to be established for voting on the proposed transactions.  Stockholders will also be able to obtain a copy
of the preliminary and definitive proxy statements once they are available, without charge, at the Securities and Exchange Commission’s (“SEC”) website at http://www.sec.gov or by directing a request to
Hicks Acquisition Company II, Inc., 100 Crescent Court, Suite 1200, Dallas, Texas 75201, telephone 214-615-2300.
HACII and its directors and officers may be deemed participants in the solicitation of proxies to HACII’s stockholders.  A list of the names of those directors and officers and a description of their interests in
HACII is contained in HACII’s annual report on Form 10-K for the fiscal year ended December 31, 2011, which is filed with the SEC, and will also be contained in HACII’s proxy statement when it becomes
available.  HACII’s stockholders may obtain additional information about the interests of the directors and officers of HACII in the transactions in reading HACII’s proxy statement and other materials to be filed
with the SEC when such information becomes available.
Safe Harbor Statement
This presentation has been prepared exclusively for the purpose of providing summary information about Appvion and its business to HACII stockholders pending the distribution of the definitive proxy
statement.  It does not constitute a solicitation for or an offer by or, on behalf of HACII or Appvion or, of any securities or investment advisory services.
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,”
“estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “poised”, “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements in this presentation include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements to differ materially from results expressed or implied by this presentation.  Such risk factors include, among others: uncertainties as to the timing of the transaction,
approval of the transaction by HACII’s stockholders; the satisfaction of other closing conditions to the transaction, including the receipt of any required regulatory approvals; costs related to the transaction;
costs and potential liabilities of Appvion relating to environmental regulation and litigation (including Lower Fox River); potential failure of Appvion’s former parent to comply with its indemnification obligations;
costs of compliance with environmental laws; Appvion’s substantial amount of indebtedness; the ability of Appvion to develop and introduce new and enhanced products, improve productivity and reduce
operating costs; Appvion’s reliance on a relatively small number of customers and third parties suppliers; the cessation of papermaking and transition to base stock supplied under the long-term supply
agreement with Domtar; the global credit market crisis and economic weakness; competitors in its various markets; volatility of raw materials costs; Appvion’s underfunded pension plans; future legislation or
regulations intended to reform pension and other employee benefit plans; and Appvion’s current owner PDC’s legal obligations to repurchase common stock from employees and former employees, which
may lead to a default under the Appvion’s agreements governing its indebtedness or constrain Appvion’s ability to reinvest and make new investments.  Actual results may differ materially from those
contained in the forward-looking statements in this presentation.  Appvion and HACII undertake no obligation and do not intend to update these forward-looking statements to reflect events or circumstances
occurring after the date of this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking
statements are qualified in their entirety by this cautionary statement.
Notes Regarding Financial Information of Appvion
The financial information and data contained in this presentation is derived from Appvion’s unaudited financial statements and may not conform to Regulation S-X.  Accordingly, such information and data may
be adjusted and presented differently in the proxy statement materials to be mailed to HACII stockholders.
Non-GAAP Information
Appvion is providing Adjusted EBITDA information, which is defined as net income of Appvion, including net income attributable to any non-controlling interest, determined in accordance with all applicable and
effective U.S. generally accepted accounting principles (“GAAP”) pronouncements up to December 31, 2011, before interest income or expense, income taxes and any gains or losses resulting from the
change in estimate relating to the Tax Receivable Agreement, depreciation, amortization, losses or gains resulting from adjustments to the fair value of the contingent consideration, stock-based compensation
expense, extraordinary or non-recurring expenses and all other extraordinary non-cash items for the applicable period as a complement to GAAP results.  Adjusted EBITDA measures are commonly used by
management and investors as a measure of leverage capacity, debt service ability and liquidity.  Adjusted EBITDA is not considered a measure of financial performance under GAAP, and the items excluded
from Adjusted EBITDA are significant components in understanding and assessing our financial performance.  Adjusted EBITDA should not be considered in isolation or as an alternative to, or superior to,
such GAAP measures as net income, cash flows provided by or used in operating, investing, or financing activities or other financial statement data presented in our consolidated financial statements as an
indicator of financial performance or liquidity.  Reconciliations of non-GAAP financial measures are provided in the accompanying tables.  Since Adjusted EBITDA is not a measure determined in accordance
with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.


Why Appvion?
2
Company focused on specialty coating formulations, microencapsulation and related know-how
#1 market position in all markets with >50% share
High growth areas including direct thermal coated products and Encapsys segment
Appvion
Leadership
Asset-light model freeing up capital for growth investments
Low execution risk on business plan (Domtar strategic alliance, non-core asset divestitures
complete)
HACII merger accelerates balance sheet transformation / deleveraging
Transformation
Complete
Successfully repositioned company for growth
Senior management rolling equity into the combined company
Management
Invested in Future
Success
Best-in-class margins (+549bps since 2009) and FCF (+$63 million/yr)
Conservative 2012PF EBITDA target of $131 million
Enhanced FCF available to fund growth, debt reduction, and shareholder value (equity
repurchases/dividends)
Strong Free Cash
Flow
(1)
Profile
(1) Defined as PF Adj. EBITDA less Capital Expenditures


Experienced and Proven Management Team
3
Chairman, President and CEO of Appvion since 2005
Prior
to
joining,
served
in
a
variety
of
senior
management
roles
within
a
diverse
range
of
sectors
that include industrial manufacturing, drug and medical devices
MBA, Northwestern University’s Kellogg School of Management
Mark Richards
Chairman, President
and CEO
Senior Vice President of Finance and CFO of Appvion since 2006
Prior to joining, served in a variety of senior financial roles within a diverse range of industries
that include banking, manufacturing and consumer packaged goods
Masters degree in finance and BBA in business, University of Iowa
Tom Ferree
Senior Vice President
and CFO
Vice President of Human Resources of Appvion since July 2009
Previously
served
in
a
variety
of
HR
roles
since
joining
Appvion
in
1982
Business Administration, Human Resources from the University of Wisconsin-Oshkosh
Senior Professional Human Resources certification since 2005
Kerry Arent
VP, Human
Resources
Senior Vice President since January 2012
Joined the Company in November 2005 as Vice President of Marketing and Strategy
Prior to joining, served in a variety of executive marketing positions with Kimberly-Clark
MBA, Northwestern University’s Kellogg School of Management
Kent Willetts
SVP, Encapsys®
Business Unit
Vice President of Thermal since April 2012
Joined the Company in April 1993 as a procurement manager
Previous roles in direct thermal and successful start-up of Encapsys®
Jamie Hillend
VP, Thermal


Global Leader in Specialty Coating Formulation and Microencapsulation
Appvion was created from over 100 years of Appleton experience, technology and know-how
Leading global converter of direct thermal coated paper and specialty carbonless products
Market leading innovative products and services
#1 North American market position with over 50% share
Exclusive distribution with key partners
High-growth
Encapsys
®
business
with
leadership
position
in
chemical
microencapsulation
technology
Highly attractive global P&G partnership
Robust growth profile with blue chip partners in established brands
Validation
of
strategic
plan
and
growth
outlook
from
widely
recognized
3
rd
party
industry
consultant
Expanded business to other commercial customers
Globally recognized brands with blue-chip customers across diverse and attractive end markets
Include
NCR
Paper*,
Appleton
®
and
Encapsys
®
Low-cost, high velocity, flexible, lean inspired business model
Established culture of excellence with demonstrated ability to reduce operating costs and improve quality and service
High margins, low capital intensity and working capital needs
Reputable
and
trusted
history
of
operating
as
a
public
reporting
company
Seasoned public filer and Sarbanes-Oxley (SOX) compliant
Independent board; adhere to best practices in corporate governance
4
* NCR Paper is a registered trademark of NCR Corporation licensed to Appleton Papers Inc.


Appvion: Successfully Repositioned
5
Domtar
strategic
alliance
a
paradigm
shift
(2012)
Industry comments: “Elegant”, “innovative”, “creative”
Strips out fixed costs and substantially reduces go forward capital expenditures
Facilitates a significant reduction of working capital
Frees up cash flow and management attention to focus on growth areas
Direct
thermal
market
leadership
investing
in
our
future
(2008)
State-of-the-art asset base installed and operating
Expanding margins and cash flow with mix shift, Domtar alliance and lean sigma operational excellence
Demonstrated ability to grow 2-3x market using coating capabilities and geographic growth
Encapsys
leveraging
a
core
technology
(2007)
50+ years of microencapsulation expertise applied to a broad range of attractive, high-growth, global markets
Rich in intellectual property and technical know-how; robust development pipeline
Proven lower capital intensity, high cash flow, scalable business model
Optimize balance of the portfolio (ongoing)
Carbonless is redirecting substantial cash flow into growing, global and profitable segments
Divested non-core assets
(1)  Defined as Adj. EBITDA less Capital Expenditures.


6
ASSET-LIGHT SPECIALTY
TRADITIONAL
COATING, FORMULATION
PAPER BUSINESS
& APPLICATION BUSINESS
MODEL
FOCUS ON GROWING,
GLOBAL DIRECT THERMAL
AND
MICROENCAPSULATION
+$107 million revenue growth (4.5% CAGR)
+549 bps EBITDA margin expansion
+20% reduction in CapEx
+$63 million increase in Free Cash Flow
(1)
Appvion: Delivering Results
6
2009
2012
(1)  Defined as Adj. EBITDA less Capital Expenditures.
Note: Segment figures do not include corporate overhead.
(EBITDA in $ Millions)
$141
$131
$73
Appvion’s Business Transformation
15.9%
15.1%
9.6%
% Margin
Carbonless
Thermal
Encapsys
$65
$63
$64
$9
$64
$68
$6
$15
$24
2009
2012PF
2013E


7
Appvion: Attractive Long-Term Equity Returns
7
Compelling
free
cash
flow
(1)
across
Appvion
portfolio
Well positioned in growing end markets
Improving margins through direct thermal mix shift
Domtar
strategic
alliance
strengthens
free
cash
flow
(1)
Provides opportunity to reinvest, pay down debt and consider a dividend
Transaction substantially enhances Appvion’s balance sheet and credit profile
Enables accelerated growth
Eliminates ESOP repurchase obligations
Provides a significant deleveraging event
Opportunity to refinance existing indebtedness and further increase free cash flow
Potential for additional upside returns
Encapsys
®
technology and operating model scalable across global markets and blue chip companies
Scale and market position provide opportunity for international expansion
(1)  Defined as PF Adj. EBITDA less Capital Expenditures.
Opportunistically acquire and integrate additional technological capabilities


Business Overview


9
Segment Snapshot
9
Specialty Coatings
Microencapsulation
Direct Thermal –
A World Leader
Carbonless –
The World Leader
Direct Thermal: Point of Sale products, mission-
critical labels and transportation and gaming
products
Carbonless: Multipart business forms and non-bank
note security papers
Trusted supplier to industry leading global customers
Proprietary technologies backed by patents and 60+
years of technical “know-how”
Business Segment
Encapsys
®
Redefining
the
Market
Products
Microcapsules that improve product performance
and reduce cost
2012PF Financial
Breakdown
(1)
EBITDA
56% from Growth
Segments
Revenue
(1)
Pro Forma for the Domtar supply agreement.
International
23%
North
America
77%
Thermal
45%
Encapsys
11%
Carbonless
44%
Leading converter of specialty coated paper products,
including direct thermal and carbonless papers
Global leader with exclusive distribution to key partners
Business Segments
Products


Direct Thermal Products: A Phenomenal Growth Story
A global leader with #1 market position in North America
Trusted partner to leading global customers
Well-invested, state-of-the-art low cost coating
capabilities
Robust proprietary technology developed over 50+
years
Produced by applying a complex thermal sensitive coating
to paper or film base stocks
Developed the technology in late 1960’s
Led market with every major enhancement
+$2.1bn global market growing at 4-7% annually
Demand driven by consumer transactions
Not susceptible to typical paper industry cycles
Primary applications include:
POS products for retail receipts and coupons
Mission-critical label, tag and ticket products
Transportation and gaming products
Key Customers
Avery Dennison, RR Donnelley and UPM Raflatac
Demonstrated Revenue Growth
10
Substantial Adj. EBITDA Improvement
($ Millions)
($ Millions)
(Margin %)
July 2008:
Coater startup
$3
$9
$18
$34
$64
$68
0%
4%
8%
12%
16%
20%
$0
$20
$40
$60
$80
2008
2009
2010
2011
2012PF
2013E
$280
$281
$342
$371
$417
$442
$0
$100
$200
$300
$400
$500
2008
2009
2010
2011
2012PF
2013E
Note: 2012PF and 2013E projections based on management guidance. Excludes intercompany eliminations and corporate overhead.


Carbonless Paper: The Market Leader
Leader in a mature, global $2.5bn market
#1 market share in North America and worldwide
Top two industry participants account for over 90% of the
domestic market
Exclusive distribution with largest merchants
Technology innovator with demonstrated ability to manage
market decline
Introduced digital product that can run on offset or digital
press
Selective export opportunities
Carbonless products used in multipart business forms (i.e.,
invoices, packing lists, application forms and receipts)
Most recognized global brand:
Security products incorporate secure technologies
(watermarks, taggants, embedded fibers, machine-readable)
Significant free cash flow generation
Minimal ongoing capital expenditure requirements
Ability to redeploy into growth segments, debt reduction
or dividends
11
Historical and Projected Revenue
Stable Adj. EBITDA Profile
($ Millions)
($ Millions)
(Margin %)
Note: 2012PF and 2013E projections based on management guidance. Excludes intercompany eliminations and corporate overhead.


Key Event: Transformational Base Stock Supply Agreement
15-year strategic alliance with Domtar provides access to high
quality, integrated base stock
Announced February 2012
Provides ~$30 million in annual EBITDA improvement
Eliminates high-cost, out-dated manufacturing facility
No net cash costs
~$30 million working capital reduction funds shutdown
costs
Continues transformation to a higher-margin, higher value-add,
lower fixed-cost converter
Focus management and capital on core competencies
Reduces
commodity
exposures
and
“locks-in”
purchasing
of base stock paper
Shutter high-cost, non-integrated base stock paper
production assets in West Carrollton
Significantly improves cash flow generation profile
Contractual;
implementation
underway
substantially
complete
by Q4 2012
12
Base Stock Transformation
25%
65%
35%
75%
2011
Pro Forma
Internal Production
Purchased from 3rd Parties


13
Microencapsulation is the delivery of chemistry in very small capsules to provide for the controlled release
of active ingredients
Produced using a chemical wall polymerization process
Low capital intensity process
Leveraged technical know how from carbonless business to
commercialize technology
Original technology introduced in the 1950s
Refreshed technology with over 60 granted patents in the
last five years
Rapidly expanding capabilities with new capsule wall technologies
Technology delivers significant value by improving product
performance at a lower cost
Extends existing product useful life by adding new benefits
Enabling technology for new products
Drives reformulations that lower product costs
Many proven applications including fragrances, flavor masking,
nutraceuticals, adhesives, biocides, and herbicides
Encapsys®
recognized as industry leader
Trusted partner to leading global customer base
Well-invested, state-of-the-art, scalable coating capabilities
“Big”
company friendly with best-in-class operating controls
and processes
Microcapsules on a human hair
(5-15 microns)
Microencapsulation: Proven technology


Encapsys
®
Partners
Procter & Gamble
Launched
partnership
with
P&G
in
2007
by
encapsulating
fragrance
for
laundry
products
Encapsys
®
provided unique solution for P&G product line
Encapsys
®
partnered with P&G and perfected fragrance encapsulation for Liquid Downy
Improved efficacy
Significant reduction in product cost
Relationship began with one product and proliferated across multiple business units and
product lines
P&G has adopted Encapsys as a strategic business platform, deploying it across its global
business units
Other Partners
14
Priority
Markets
Products
Household
Laundry care
Toilet products
Acquisition targets
Food / Pharma
Physical encapsulation
FDA compliant
Phase change material
Industrial
Biocides
Paints and coatings
Personal Care
Antiperspirants
Hair care
Herbicides
AgChem
Insecticides
Fungicides


Microencapsulation: Serving a sizeable growing market
15
$4 billion global market growing 10% annually
Wide market appeal with applications in food, pharma,
AgChem, industrial, paints & coatings, oil & gas,
personal and household care, and nutraceuticals
Strategic review by widely recognized specialty chemical
consulting firm
Endorsed
projections
that
Encapsys®
can
grow
to
multiples of its current size by 2016
Addressable market increased from $2 billion to $4
billion
Opportunity to grow faster than current model by
acquiring capabilities and products
Focused on large joint development pipeline to drive
growth
16 development partners and greater than 20 active
projects under development (preponderance with
Fortune 500 companies)
Partners include Troy, Entropy and a global Fortune
500 consumer packaged goods companies
Demonstrated Revenue Growth
Robust Adj. EBITDA Growth Profile
($ Millions)
($ Millions)
(Margin %)
Note: 2012PF and 2013E projections based on management guidance. Excludes intercompany eliminations and corporate overhead.


Financial Summary


Consolidated Financial Summary
Revenue
Adjusted EBITDA
Capital Expenditures
(1)
Free Cash Flow
(1)(2)
Note:
2012PF
and
2013E
projections
based
on
management
guidance.
2012
PF
Adj.
EBITDA
and
capital
expenditures
Pro
Forma
for
Domtar
transaction.
See
EBITDA
reconciliation on page 29.
(1) Excludes Capital Expenditures related to Domtar transaction implementation in 2012 and 2013.
(2) Defined as Adj. EBITDA less Capital Expenditures.
17
($ Millions)
($ Millions)
($ Millions)
($ Millions)
(EBITDA Margin %)
$762
$850
$857
$869
$887
2013E
$650
$750
$850
$950
2009
2010
2011
2012PF
5%
8%
10%
13%
15%
18%
20%
$0
$50
$100
$150
2009
2010
2011
2012PF
2013E
$73
$79
$89
$131
$141
$15
$12
$25
$18
$16
$20
$27
$0
$10
$20
$30
2009
2010
2011
2012E
2013E
$48
$61
$73
$111
$114
$0
$20
$40
$60
$80
$100
$120
2009
2010
2011
2012PF
2013E


EBITDA Bridge Analysis
18
2011A to 2013E
(2)
(1)
Unaudited run-rate EBITDA for the four months ending April 2012. Excludes pension benefit and contract savings.
(2)
Contracted EBITDA improvement is annualized to reflect full-year impact of Domtar Supply Agreement.
(3)
Impact of lower pension expense due to freeze of salaried defined benefit.
Additional ~$30 million in contracted annualized EBITDA improvement
Ongoing EBITDA benefit due to reduced pension expense
$102
Run-Rate
(1)
(3)
$89
$8
$28
$6
$131
$10
$141
$75
$100
$125
$150
2011A
Business
Growth
Contract
Savings
Lower Pension
Expense
2012PF Adj.
Business
Growth
2013E
Base
business
EBITDA
ahead
of
plan
(1)


19
Current and Post-Transaction Balance Sheet
19
Assumes
net
proceeds
from
the
transaction
are
applied
as
cash
to
balance
sheet
that
will
be
utilized
for
general
corporate
purposes,
debt
reduction,
and
warrant
repurchases.
Includes
$18.2
million
of
additional
2
Lien
notes
issued
upon
change
of
control.
Assumes all Public Warrantholders elect for Option A of the proposed warrant amendment (as detailed on page 29), resulting in cash proceeds used for warrant
repurchases
of
$9.4
million
(assuming
payment
of
$0.625
per
each
of
15
million
outstanding
public
warrants
at
closing).
Assumes 2012E PF Adj. EBITDA of $131 million.
(2)
Actual as of
As Adjusted for
4/1/2012
this Transaction
(1)
Interest Rate
Maturity
Call Date
Cash & Equivalents
7
$                       
108
$                   
Revolving Credit Facility
-
$                      
-
$                      
Variable
Feb -
2015
Senior Secured 1st Lien Notes
301
301
10.500%
Jun -
2015
Mar -
2013
2nd Lien Notes
162
180
11.250%
Dec -
2015
NA
Senior Subordinated Notes
32
32
9.750%
Jun -
2014
Jun -
2012
Industrial Revenue Bonds
9
9
Variable
2013 / 2017
State of Ohio Loan
8
8
Variable
May -
2017
Columbia County, Wisconsin Forgivable Note
0
0
Variable
May -
2019
Total Debt
512
$                   
530
$                   
Net Debt
505
$                   
422
$                   
Net Debt / PF Adj. EBITDA
(3)
3.9x
3.2x
(1)
Note: Assumes no HACII shareholder redemptions.
(2)
(3)
nd


Transaction Summary


Transaction Overview
Appvion
to
become
publicly
traded
through
a
business
combination
with
Hicks
Acquisition Company II, Inc. (Nasdaq: HKAC)
Post-closing Appvion will trade on Nasdaq under ticker APVN
Appvion
enterprise
value
of
$684
million
(1)
Transaction
Appvion will receive up to $149.3 million in cash, less fees, expenses and HACII
redemptions, which will be used to delever balance sheet and repurchase public
warrants (as described in footnote 2 below)
Pro
Forma
net
debt
of
$422
million
(2)
(3.2x
2012E
PF
Adjusted
EBITDA)
at
close
Appvion employee shareholders will receive 9.6 million shares and retain
approximately
Earn-out shares provide significant shareholder-aligned incentive
Consideration
Management team led by Mark Richards, Chairman and CEO
Management intends to roll a substantial portion of its long-term incentive earnings
Board will be comprised of 9 members (6 independent directors with the remaining
representatives from Appvion and Hicks)
Management and Board
July 2012
Expected Closing
21
(1)
Excludes value of 3.0 million earnout shares issued in connection with the transaction.
(2)
Assumes all Public Warrantholders elect for Option A of the proposed warrant amendment (as detailed on page 29), resulting in cash proceeds used for warrant
repurchases of $9.4 million (assuming payment of $0.625 per each of 15 million outstanding public warrants at closing).
(3)
Ownership  percentages are calculated as basic ownership and exclude warrants, options and redemptions from the ownership calculation. Any redemptions by HACII
shareholders would proportionally lower HACII’s ownership percentage and raise the ownership percentage of ESOP participants.
37%
ownership
(3)


Transaction Valuation and Ownership
Pro Forma Valuation
Pro Forma Appvion Ownership
(2)
22
Appleton
37%
HAC
Founders
Public
57%
Employees
7%
(4)
Implied Enterprise Value
684
$        
Pro Forma Net Debt
(1)
(422)
Pro Forma Fully Diluted Equity Value
262
$        
Fully Diluted Shares (mm)
(2)
26.3
Implied Share Price
9.95
$       
Implied Multiple
(3)
2012PF
2013E
TEV / PF Adj. EBITDA
5.2x
4.9x
TEV / PF Adj. EBITDA -
CapEx
6.2x
5.4x
(1)
Assumes all Public Warrantholders elect for Option A of the proposed warrant amendment (as detailed on page 29), resulting in cash proceeds used for warrant
repurchases of $9.4 million (assuming payment of $0.625 per each of 15 million outstanding public warrants at closing).
(2)
Excludes 1.0 million earnout shares with a strike price of $12.50 and 2.0 million earnout shares with a strike price of $15.00 issued in connection with the transaction.
(3)
Based on PF Adj. EBITDA of $131 and $141 million and capital expenditures of $20 and $15 million in 2012E and 2013E, respectively.
(4)
Includes current and former employees.


Comparable Companies –
Financial Benchmarking
Net Debt / 2012E EBITDA
23
Note: As of 6/21/2012. Comparable companies includes: Wausau Paper (WPP), Neenah Paper (NP), Schweitzer-Mauduit (SWM) and Glatfelter Paper (GLT).
(3)
2012E EBITDA Margin %
2011A –
2013E EBITDA Growth
2012E EBITDA –
CapEx Margin %
(1)
(1)
(1)
(2)
(1)
25.1%
15.1%
14.1%
10.4%
9.0%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
SWM
APVN
NP
GLT
WPP
25.8%
11.7%
9.7%
7.2%
6.3%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
APVN
NP
WPP
GLT
SWM
12.8%
11.0%
7.7%
4.2%
NA
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
APVN
NP
WPP
GLT
SWM
3.2x
1.7x
1.3x
1.2x
0.3x
0.0x
1.0x
2.0x
3.0x
4.0x
5.0x
6.0x
APVN
NP
WPP
GLT
SWM
(1)
Based on PF Adj. EBITDA of $131 and $141 million in 2012E and 2013E, respectively.
(2)
Excludes $152 million of capital expenditures related to tissue expansion.
(3)
As presented in the offering contemplated herein. Assumes 0% HACII shareholder redemptions and assumes all Public Warrant holders elect Option A (as defined on page 29) of
the proposed warrant amendment resulting in a cash use of $9.4 million at closing of the transaction.


Comparable Companies –
Valuation Benchmarking
24
TEV / 2012E EBITDA
(1)
Note: As of 6/21/2012. Comparable companies include Specialty Paper peers: Wausau Paper (WPP), Neenah Paper (NP), Schweitzer-Mauduit (SWM), Glatfelter Paper (GLT) and
Specialty Chemical / Microencapsulation peers: Balchem Corp. (BCPC).
TEV / 2013E EBITDA
(1)
TEV / 2012E EBITDA -
CapEx
(1)(2)
(3)
12.8x
13.1x
14.0x
13.0x
Appvion
Specialty Paper Comparables
Specialty Chemical /
Microencapsulation Comparables
6.5x
5.5x
5.3x
5.2x
5.1x
0.0x
2.0x
4.0x
6.0x
BCPC
WPP
NP
GLT
APVN
SWM
5.6x
5.4x
5.2x
5.0x
4.9x
0.0x
2.0x
4.0x
6.0x
BCPC
WPP
NP
SWM
GLT
APVN
16.5x
13.3x
7.6x
7.0x
6.2x
NA
0.0x
3.0x
6.0x
9.0x
12.0x
15.0x
18.0x
BCPC
GLT
WPP
NP
APVN
SWM
(1)
(2)
(3)
As presented in the offering contemplated herein. Assumes 0% HACII shareholder redemptions and assumes all Public Warrant holders elect Option A (as defined on page 29) of the
proposed warrant amendment resulting in a cash use of $9.4 million at closing of the transaction.
Based on PF Adj. EBITDA of $131 and $141 million in 2012E and 2013E, respectively.
Excludes $152 million of capital expenditures related to tissue expansion.


Multiple Avenues to Deliver Shareholder Value
25
Deleveraging
Story
Leading
Market
Positions in
Growth
Markets
Strong Free
Cash Flow
Technology
Innovator
Asset Light
Model
Blue Chip
Sponsor
Attractively
Priced
Proven and
Experienced
Management
Team


Appendix


Hicks Equity Partners
Led by Tom Hicks, Chairman of the Board
Founder of one of the most successful private investment firms with 35+ years of
private equity investing experience
Supported by team of experienced investment professionals who, combined with Tom
Hicks, have over 150 years of private equity and public company experience
Extensive relationships with other financial sponsors, management teams and financial
intermediaries
Raised $150 million in October 2010 for Hicks Acquisition Company II, Inc. (“HAC II”)
Successfully raised $552 million for Hicks Acquisition Company I, Inc. in September 2007
Merged with Resolute Energy in September 2009
One of the most successful transactions for SPACs of similar size
Blue Chip Sponsor
27


Sources & Uses and Historical Financial Summary
28
($ Millions)
Sources & Uses
Financial Summary
2008A
2009A
2010A
2011A
2012PF
2013E
(1)
Revenue
855
$     
762
$     
850
$     
857
$     
869
$     
887
$     
% Growth
NA
(10.9%)
 
11.6%
  
0.9%
    
1.3%
    
2.1%
    
Gross Profit
171
$     
159
$     
165
$     
170
$     
216
$     
229
$     
% Margin
20.1%
  
20.8%
  
19.5%
  
19.8%
  
24.9%
  
25.8%
  
Adjusted EBITDA
66
$       
73
$       
79
$       
89
$       
131
$     
141
$     
% Margin
7.7%
    
9.6%
    
9.3%
    
10.4%
  
15.1%
  
15.9%
  
Adjusted EBIT
13
$       
17
$       
30
$       
41
$       
91
$       
98
$       
% Margin
1.5%
    
2.2%
    
3.5%
    
4.7%
    
10.4%
  
11.1%
  
Capital Expenditures
(2)
95
$       
25
$       
18
$       
16
$       
20
$       
27
$       
% Sales
11.1%
  
3.2%
    
2.1%
    
1.8%
    
2.3%
    
3.0%
    
Sources of Funds
Cash Held in Trust
(3)
143
$       
Total Sources
143
$       
Uses of Funds
Cash to Balance Sheet
(4)
101
$       
Warrant Repurchase
(5)
9
Change of Control Payments
(6)
13
Legal & Accounting
5
Fees, incl. ESOP Advisory
12
Other Transaction Costs
1
Total Uses
143
$       
(1)
Figures do not reflect the impact of the Business Combination with Hicks Acquisition Company II, Inc.
(2)
Excludes Capital Expenditures related to Domtar transaction implementation in 2012 and 2013.
(3)
Based on actual cash held in trust as of April 1, 2012, net of assumed redemption of 0%. Net of Deferred Underwriting & Selling Group fees of $6.7 million.
(4)
Assumes net proceeds from the transaction are applied as cash to balance sheet that will be utilized for general corporate purposes and debt reduction.
(5)
Assumes all Public Warrantholders elect for Option A of the proposed warrant amendment (as detailed in page 29), resulting in cash proceeds used for warrant
repurchases of $9.4 million (assuming payment of $0.625 per each of 15 million outstanding public warrants at closing).
(6)
Includes costs associated with existing incentive plans and necessary consents.


HACII and Appvion have proposed to amend the terms of the warrant agreement to reduce by half the number
of shares of common stock of HACII issuable upon exercise of HACII’s outstanding warrants, subject to a
potential minor adjustment as detailed under Option B
This amendment must be approved by warrant holders who own at least 65 percent of the outstanding public
warrants
Public warrant holders would be able to elect one of two options:
Option A:
amended warrant plus cash
Each existing warrant would be amended to be exercisable for half a share (instead of one full share),
plus
Payment of $0.625 per warrant at closing
Economic equivalent of receiving $1.25 per foregone warrant
Option B:
amended warrant plus earnout share right
Each existing warrant would be amended to be exercisable for half a share (instead of one full share),
plus
Receive a right to purchase an additional 0.0879 shares per warrant
Exercisable at $0.0001 once the common stock has traded at $12.00 per share for a defined period of
time prior to the fifth anniversary of the closing of the transaction
In the case of Option B, the warrant holder would have the ability to exercise one part of the warrant
independently from the other
HACII’s founder will receive economic equivalent of Option B, but in earnout shares that will be subject to
forfeiture
Warrant holders who do not make an election will automatically receive Option A
Public election of Option B is capped at warrants exercisable for 400,000 shares
Summary of Proposed Warrant Amendment
29


Pro Forma Adjusted EBITDA Reconciliation
30
($ Millions)
2009
2010
2011
2012PF
2013E
(1)
(Loss)
Income
from
Continuing
Operations
Before
Income
Taxes
24
$         
(35)
$        
(2)
$          
(103)
$      
55
$         
Depreciation, Amortization and Other
57
51
49
40
43
Net Interest Expense
(43)
65
61
54
48
Restructuring Expense
-
-
-
123
(5)
Net Debt Extinguishment Expense
51
7
-
-
-
Litigation Settlement, net
-
-
(23)
-
-
Foreign Exchange (Gain) Loss
(2)
1
1
-
-
Other Income
-
(1)
0
4
-
EBITDA
87
$         
88
$         
86
$         
117
$       
141
$       
Environmental Insurance Expense Recovery
-
(9)
-
-
-
Debt Extinguishment Expenses
4
-
-
-
-
Alternative Fuels Tax Credit
(18)
-
-
-
-
Litigation Settlement, net
-
-
3
-
-
Domtar Suppy Agreement Run-Rate Adjustment
-
-
-
14
-
Adjusted EBITDA
73
$         
79
$         
89
$         
131
$       
141
$       
(1) Represents the median of management forecast. Figures do not reflect the impact of the Business Combination with Hicks Acquisition Company II, Inc.